PTAB Sides with Broad Institute over CVC on CRISPR Patent Priority

The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) has sided with the Broad Institute over the University of California (UC), the University of Vienna, and CRISPR pioneer and Nobel co-laureate Emmanuelle Charpentier, PhD, (collectively called CVC) in the bitter battle royal over who invented the gene-editing technology in eukaryotic cells.

Related Keywords

California ,United States ,Zurich ,Züsz ,Switzerland ,Vienna ,Wien ,Austria ,Berlin ,Germany ,Luciano Marraffini ,Krzysztof Chylinski ,Emmanuelle Charpentier ,Martin Jinek ,Jacob Sherkow ,Jamesc Mullen ,Jennifer Doudna ,University Of California ,Broad Institute ,Twitter ,Us Court ,Trademark Office ,University Of Illinois ,Max Planck Institute Of Infection Biology ,Rockefeller University ,Fellows Of Harvard College ,College Of Law ,University Of Vienna ,University Of Zurich ,Patent Trial ,Appeal Board ,Harvard College ,Max Planck Institute ,Infection Biology ,Genomic Biology ,Nobel Prize ,Federal Circuit ,Patent Application ,Editas Medicine ,